Evidence map›Paper›PMID 41946259›Full record

ArticleStem cell research2026

Generation of two induced pluripotent stem cell lines from hypertrophic cardiomyopathy patients carrying MYBPC3 mutations.

Catherine A Wu, Matthew A Wu, Shane R Zhao, Junyi Sun, Amira G Flores-Banuelos, Parker Walther, Matthew Wheeler, Nazish Sayed

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Stem cell research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Catherine A WuStanford Cardiovascular Institute, Stanford University, Stanford, CA 94305, USA.
Matthew A WuStanford Cardiovascular Institute, Stanford University, Stanford, CA 94305, USA.
Shane R ZhaoStanford Cardiovascular Institute, Stanford University, Stanford, CA 94305, USA; Department of Medicine, Division of Cardiology, Stanford University, Stanford, CA 94305, USA.
Junyi SunStanford Cardiovascular Institute, Stanford University, Stanford, CA 94305, USA; Department of Medicine, Division of Cardiology, Stanford University, Stanford, CA 94305, USA.
Amira G Flores-BanuelosStanford Cardiovascular Institute, Stanford University, Stanford, CA 94305, USA.
Parker WaltherGreenstone Biosciences, Palo Alto, CA, USA.
Matthew WheelerDepartment of Medicine, Division of Cardiology, Stanford University, Stanford, CA 94305, USA.
Nazish SayedStanford Cardiovascular Institute, Stanford University, Stanford, CA 94305, USA; Department of Surgery, Division of Vascular Surgery, Stanford University, Stanford, CA 94305, USA. Electronic address: sayedns@stanford.edu.

Funding

BIOREPOSITORY OF HUMAN INDUCED PLURIPOTENT STEM CELLSFORCARDIOVASCULAR DISEASES (BHIPSC-CVD) - TASK AREA B75N92020D00019 · NHLBI · STANFORD UNIVERSITY · PI WU, JOSEPH · 2021 to 2024
$4.0M
Deciphering the Endothelial Cell-Cardiomyocyte Crosstalk in LMNA CardiomyopathyR01HL158641 · NHLBI · STANFORD UNIVERSITY · PI SAYED, NAZISH · 2021 to 2025
$2.2M
Unraveling the role of endothelium in chemotherapy-induced cardiotoxicityR01HL161002 · NHLBI · STANFORD UNIVERSITY · PI SAYED, NAZISH · 2022 to 2025
$1.6M
Unraveling Endothelial-CardiomyocyteCrosstalk in Cardiomyopathy: An Integrated Multimodal ApproachR35HL183578 · NHLBI · STANFORD UNIVERSITY · PI Nazish Sayed · 2026 to 2026
$770k
NHLBI NIH HHS 75N92020D00019NHLBI NIH HHS R01 HL158641NHLBI NIH HHS R01 HL161002NHLBI NIH HHS R35 HL183578
6 · The paper itself

Abstract

Hypertrophic cardiomyopathy (HCM) is a prevalent inherited cardiac disorder characterized by left ventricular hypertrophy and contractile dysfunction. Mutations in sarcomeric genes, particularly cardiac myosin-binding protein C (MYBPC3), are a leading cause of HCM. Here, we generated two induced pluripotent stem cell (iPSC) lines from peripheral blood mononuclear cells of patients carrying distinct MYBPC3 mutations (c.2490dupT and c.1800delA). Both lines displayed normal morphology, stable karyotypes, robust expression of pluripotency markers, and trilineage differentiation potential. These patient-specific iPSC lines provide a valuable platform for modeling MYBPC3-associated HCM and enable mechanistic and therapeutic studies of inherited cardiac disease.

Indexed as

Cardiomyopathy, HypertrophicCarrier ProteinsInduced Pluripotent Stem CellsMutationCell DifferentiationCell LineFemaleHumansMaleMyosin Binding Protein CCarrier ProteinsMyosin Binding Protein CCardiac myosin-binding protein C (MYBPC3)Hypertrophic cardiomyopathy (HCM)Induced pluripotent stem cells (iPSCs)

Identifiers

PMID41946259
PMCPMC13292117

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.